Zedenoleucel

泽德诺仑赛

Report date: 2022/08/08 11:24:16

Base Information

Drug NameZedenoleucel
Drug Alias NameTAA-specific CTLsMultiTAA-specific T cell therapyMultiTAA T cells StageMultiTAA-specific T cellsAutologous cytotoxic T-cell therapeutic - Marker Cell Therapeutics +[10] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesOvarian NeoplasmsPancreatic Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of MedicineMarker Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of MedicineMarker Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesOvarian NeoplasmsPancreatic Neoplasms +[11] 
Inactive IndicationsHematopoietic stem cell transplantation (HSCT)

Other Information

ATC CodeN/A
Related LinksN/A